Janux Therapeutics (JANX) CEO Campbell acquired 7,000 shares at $4.21
Insider transactions reported
David Alan Campbell (President and CEO at Janux Therapeutics Inc., JANX) reported that they acquired 7,000 shares at $4.21 on Jul 8, 2026. After these transactions the filing shows 388,582 shares held directly.
- Reporting person
- Campbell David Alan
- Role
- President and CEO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Exercise or conversion of a derivative (M) | Common Stock | +7,000 | $4.21 | $29.5K | 388,582 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Exercise or conversion of a derivative (M) | Stock Option (right to buy)On 7,000 Common Stock1 | -7,000 | - | - | 697,550 direct |
Holdings before and after
- Common Stock: 381,582 to 388,582 direct
- Stock Option (right to buy): 704,550 to 697,550 direct
Footnotes from the filing
- 1. Immediately exercisable.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Campbell report in this JANX Form 4?
David Alan Campbell (President and CEO at Janux Therapeutics Inc., JANX) reported that they acquired 7,000 shares at $4.21 on Jul 8, 2026. After these transactions the filing shows 388,582 shares held directly.
How many JANX shares does Campbell hold after this filing?
The filing shows 388,582 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for JANX
Across the 15 sessions after earlier JANX headlines, the stock closed higher 8 times and lower 7 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JANX | SPY |
|---|---|---|---|
| May 8, 2026 | Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | -2.5% | +0.8% |
| Apr 28, 2026 | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development | -4.8% | -0.5% |
| Apr 20, 2026 | Janux Therapeutics downgraded by Barclays with a new price target | +0.3% | -0.2% |
| Apr 17, 2026 | Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 | +4.1% | +1.2% |
| Apr 15, 2026 | Janux Therapeutics downgraded by UBS with a new price target | -1.3% | +0.8% |
| Apr 1, 2026 | Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment | +4.4% | +0.8% |
Earlier insider filings at JANX
- Jun 13, 2026Director Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)
- Jun 13, 2026Director Simson Jake was granted 5,500 shares (SEC Form 4)
- Jun 13, 2026Director Hernday Natasha was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)
- Jun 13, 2026Director Kung Winston was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)
- Jun 13, 2026Director Capps Vickie L was granted 5,500 shares, increasing direct ownership by 7% to 79,598 units (SEC Form 4)
Keep researching JANX
- JANX insider tradesEvery buy and sale reported by Janux Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- JANX earnings historyPast Janux Therapeutics Inc. earnings releases, newest first.
- JANX financial statementsRevenue, profit, cash flow and balance sheet from Janux Therapeutics Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow JANX and get a push notification the moment its next story breaks.